Imperial College London
Alternate

ProfessorDianaBilton

Faculty of Medicine, National Heart & Lung Institute

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)7801 067 057diana.bilton

 
 
//

Location

 

Fulham RoadRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mohindru:2019:10.1016/j.jcf.2019.01.007,
author = {Mohindru, B and Turner, D and Sach, T and Bilton, D and Carr, S and Archangelidi, O and Bhadhuri, A and Whitty, JA},
doi = {10.1016/j.jcf.2019.01.007},
journal = {Journal of Cystic Fibrosis},
pages = {452--460},
title = {Health economic modelling in Cystic Fibrosis: a systematic review},
url = {http://dx.doi.org/10.1016/j.jcf.2019.01.007},
volume = {18},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: Cystic Fibrosis (CF) is a heritable chronic condition. Due to the genetic and progressive nature of CF, a number of interventions are available for the condition. In the United Kingdom (U.K.) average annual cost of CF treatment is between €49,000 to €76,000 (2012) per patient [1]. A review of health economic modelling studies is warranted to provide decision makers and researchers with an in depth understanding of modelling practices in CF and guidance for future research. METHODS: Online searches were performed in the 5 databases, studies were included if they were: a) Model based economic evaluation for management of Cystic Fibrosis. Articles were restricted to English language only, but no restriction was applied on publication year. RESULTS: Nine studies were reviewed, most were Markov cohort models. Models evaluated pharmaceutical interventions and drug adherence. Modelling structure was consistent across most articles and a range of sources were used to populate the models. Cost and utility data were based on different sources and elicitation methods respectively. The majority of models failed to incorporate significant health events which impact both cost and disease progression. CONCLUSION: In our review we observed a lack of, application of European Medicines Agency (EMA) guidelines for clinical trial endpoints, model structure justifications and lastly, health-related quality of life derived utility information around important clinical events. Future work around conceptual modelling of CF progression, utility valuation of significant health events and meeting EMA guidelines for trial reporting is encouraged.
AU  - Mohindru,B
AU  - Turner,D
AU  - Sach,T
AU  - Bilton,D
AU  - Carr,S
AU  - Archangelidi,O
AU  - Bhadhuri,A
AU  - Whitty,JA
DO  - 10.1016/j.jcf.2019.01.007
EP  - 460
PY  - 2019///
SN  - 1569-1993
SP  - 452
TI  - Health economic modelling in Cystic Fibrosis: a systematic review
T2  - Journal of Cystic Fibrosis
UR  - http://dx.doi.org/10.1016/j.jcf.2019.01.007
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30738801
UR  - http://hdl.handle.net/10044/1/68555
VL  - 18
ER  -
Download